Compugen (CGEN) Income towards Parent Company (2009 - 2026)
Compugen (CGEN) posted quarterly Income towards Parent Company of $7.7 million for Q1 2026, up 7.59% year-over-year from $7.1 million in Q1 2025, and down 86.5% on a QoQ basis from $56.7 million in Q4 2025.
Compugen (CGEN) Income towards Parent Company (2009 - 2026) Analysis & Trends
Compugen has reported Income towards Parent Company for 18 years, with the latest figure at $7.7 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at $7.7 million, up 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.9 million (up 772.34% YoY), and the FY2025 annual result was $35.3 million, up 348.35% from the prior year.
- Income towards Parent Company eased to $7.7 million in Q1 2026, from $56.7 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $56.7 million in Q4 2025 and troughed at -$28.0 million in Q2 2023.
- A 5-year average of $1.4 million and a median of -$3.1 million in 2022 frame the typical range for Income towards Parent Company.
- The widest annual swing landed in 2023, when Income towards Parent Company tumbled 198.03%; it then jumped 1027.53% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$3.1 million in 2022, then jumped by 414.13% to $9.7 million in 2023, then slumped by 162.98% to -$6.1 million in 2024, then jumped by 1027.53% to $56.7 million in 2025, then sank by 86.5% to $7.7 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $7.7 million in Q1 2026, $56.7 million in Q4 2025, and -$6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Compugen | 227.88 Mn | 136.13 Mn | 352,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 56.74 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -21.61 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | -6.12 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | -16.62 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 9.71 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | -3.09 Mn |
| Sep 30, 2022 | -11.75 Mn |
| Jun 30, 2022 | 28.56 Mn |
| Mar 31, 2022 | -9.71 Mn |
| Dec 31, 2021 | -8.65 Mn |
| Sep 30, 2021 | -8.18 Mn |
| Jun 30, 2021 | -9.50 Mn |